使用钙通道阻滞剂患者青光眼进展风险:倾向匹配队列研究
本研究利用TriNetX美国协作网络开展回顾性队列分析,纳入轻度至中度原发性开角型青光眼(POAG)且随访超过6个月的患者,按是否使用钙通道阻滞剂(CCB)分层,经倾向评分1:1匹配后比较进展为重度POAG的风险。结果显示,使用二氢吡啶类CCB(RR 1.67,95%CI 1.23-2.27)和非二氢吡啶类CCB(RR 3.62,95%CI 1.97-6.62)的患者进展为重度POAG的风险均显著高于对照组。
要点
- 二氢吡啶类CCB使用与重度POAG进展风险升高相关(RR 1.67)。
- 非二氢吡啶类CCB使用与重度POAG进展风险升高更明显(RR 3.62)。
- 研究排除既往重度POAG及使用ACEI、ARB或β受体阻滞剂者。
核心结论
- 二氢吡啶类和非二氢吡啶类CCB均与轻中度POAG进展为重度POAG的风险升高相关。
研究设计与样本
- 回顾性队列分析,使用TriNetX美国协作网络识别轻中度POAG且随访超过6个月的患者。
- 按CCB使用分层,排除既往重度POAG或使用ACEI、ARB、β受体阻滞剂者。
- 采用倾向评分1:1匹配控制年龄、性别、种族、族裔和高血压,计算风险比(RR)及95%CI。
主要发现
- 匹配后共纳入7446例患者:对照组3723例,二氢吡啶类CCB组3039例,非二氢吡啶类CCB组684例。
- 二氢吡啶类CCB组进展为重度POAG的风险显著高于对照组(RR 1.67;95%CI 1.23-2.27)。
- 非二氢吡啶类CCB组进展为重度POAG的风险显著高于对照组(RR 3.62;95%CI 1.97-6.62)。
临床怎么用
- 对轻中度POAG患者使用CCB时,应关注青光眼进展风险并加强监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the potential impact of calcium channel blocker (CCB) use on the progression of mild to moderate POAG to the severe stage. METHODS: A retrospective cohort analysis was conducted using the TriNetX United States Collaborative Network to identify patients with mild or moderate POAG and more than 6 months of follow-up data. Patients were stratified by CCB use. The primary outcome was disease progression to severe POAG at any time point after the initial diagnosis, identified using International Classification of Diseases, Tenth Revision, code H40.1193. Patients with prior severe POAG or those prescribed angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or beta-blockers were excluded. Propensity score matching (1:1) was conducted to control for age, sex, race, ethnicity, and hypertension. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated. RESULTS: After propensity score matching, 7446 patients were included: 3723 controls (no CCB use), 3039 taking dihydropyridine CCBs (dCCBs), and 684 taking nondihydropyridine CCBs (ndCCBs). The risk of severe POAG was significantly higher in patients using dCCBs (RR, 1.67; 95% CI, 1.23-2.27) and ndCCBs (RR, 3.62; 95% CI, 1.97-6.62) compared with controls. CONCLUSIONS: Both dCCBs and ndCCBs were associated with an increased risk of progression to severe POAG in patients with mild to moderate disease. Further research is needed to elucidate the underlying mechanisms of this association.
引用
- Qozat I, Abubaker Y, Vasu P, et al. Risk of Glaucoma Progression in Patients Using a Calcium Channel Blocker: A Propensity-Matched Cohort Study. Invest Ophthalmol Vis Sci. 2026. PMID: 42165646. doi:10.1167/iovs.67.5.59
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。